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Multiple myeloma accounts for approximately 10% of all haema-
tological malignancies. It is a clonal proliferation of plasma cells.
In 98% of patients there is a detectable paraprotein (a monoclonal
immunoglobulin heavy chain and/or light chain) in the blood or
urine. Normal immunoglobulin levels and the ability to mount a
humoural response to infection or vaccination are reduced (Fahey
et al, 1963). In addition, chemotherapy-induced suppression of the
bone marrow and immune system, depression of circulating
CD19+ cells, impaired renal function, immobility and, late in the
disease, defective cell mediated immunity all contribute to an
increased risk of infection in these patients (Deresinski and
Stevens, 1974; Norden, 1980; Luque et al, 1998). In the early
stages and plateau phase bacterial infections with common organ-
isms such as Streptococcus pneumoniae, Haemophilus influenzae
and Escherichia coli predominate (Savage et al, 1982). During the
terminal stage of the disease and following chemotherapy or bone
marrow transplantation the range of infections increases and
includes viruses and fungi (Ringden, 1997). The use of prophyl-
actic agents such as co-trimoxazole, oral antifungal preparations
and acyclovir has become standard supportive therapy and has
reduced the incidence of infection associated with modern treat-
ment regimens. Despite this, infection remains the leading cause
of death in patients with this disease.
We have undertaken a pilot study in 52 patients with multiple
myeloma in order to: (i) estimate the degree of susceptibility of
this population to infection with S. pneumoniae, H. influenzae type
b (Hib) and influenza virus and (ii) measure the serological
response to three vaccines administered simultaneously.
MATERIALS AND METHODS
Patient characteristics
Ethical approval was obtained before commencing this study.
Patients attending the weekly myeloma outpatient clinic at the
Christie Hospital during October and November 1997 were
offered vaccination against influenza, S. pneumoniae and  H.
influenzae type b (Hib). Exclusion criteria were allergy to egg,
previous influenza vaccine within 6 months, and previous pneu-
mococcal vaccine within 5 years. Written informed consent was
required and patients were able to choose whether to receive all or
some of the offered vaccines. The vaccines used in the study were:
Fluvirin (Evans Medical) containing inactivated A/Singapore/6/86
(H1N1), A/Wuhan/359/95 (H3N2) and B/Beijing/184/93;
Pneumovax II (Pasteur-Merieux), a 23-valent vaccine; and ACT-
HIB (Farillon). All were administered as deep subcutaneous injec-
tions at separate sites according to manufacturers’ instructions.
Patients were asked to report adverse reactions to vaccination.
Fifty-two patients (30 male, 22 female) were recruited. The
median age was 55.4 years (range 31.8–76.4 years). Thirty-nine
patients had IgG myeloma, six IgA, one IgD, one systemic AL
amyloidosis, four Bence Jones myeloma and one non-secretory
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3.0  ´ 109 l–1 on the day of vaccination. The median granulocyte
count of these eight patients was 1.6 ´ 109 l–1. Thirty-five patients
had normal levels of polyclonal IgG (local normal range 8–
16 g l–1) and 17 patients had levels below 8 g l–1 on the day of
vaccination. In cases of IgG myeloma, this was calculated by
subtracting the paraprotein from the total IgG.
Sixteen patients had received chemotherapy within the week
prior to vaccination, seven patients had undergone high-dose
therapy (melphalan/total body irradiation) and autologous periph-
eral blood stem cell transplant within the preceding 6 months.
Twenty-one patients were undergoing treatment with interferon
a 3 MU three times per week during the course of the study.
Forty-seven patients received all three vaccinations and five
patients received two of the three offered.
In order to estimate clinical efficacy of influenza vaccination,
patients were asked to report episodes of upper respiratory tract
infections and given a swab kit with instructions for taking throat
and nose swabs for influenza virology.
Serological methods
Peripheral blood was taken prior to vaccination to estimate base-
line serology and at 4–6 weeks following vaccination to measure
any increase in specific antibody titres. Serum was stored frozen at
–40°C prior to analysis. Anti-capsular polysaccharide antibodies
to S. pneumoniae and Hib were measured by antigen-specific
enzyme-linked immunosorbent assay (ELISA) and radio antigen
binding assay (RABA) respectively (Hazelwood et al, 1993) at
the Department of Immunology, City Hospital NHS Trust,
Birmingham. Antibodies to the three inactivated influenza strains
were assayed by haemagglutination inhibition (HI) (Chakraverty
1971) at the Influenza Laboratory, Central Public Health
Department, London.
Interpretation of results
Antibody titres to capsular polysaccharide elements of S. pneumo-
niae and Hib for individual patients were compared with reference
values corresponding to the geometric mean titre (GMT) obtained
from a healthy UK adult population: 1:640 and 1.02 mg ml–1
respectively (Hazelwood et al, 1993). Protective titres were
defined as levels above the GMT for these two organisms. For the
three influenza antigens, a HI titre of ³ 1/40 was considered
protective for each antigen separately (Hobson et al, 1972). The
pre- and post-immunization GMTs allowed further estimation of
the population susceptibility and efficacy of vaccination. In order
to calculate the GMT for influenza strains, haemagglutination
titres below the limit of detection of the assay (1/10) were assigned
a value of 5 (Lyall et al, 1997). For individual patients response to
vaccination was also determined, a good response being defined as
a fourfold increase in antibody titre as a result of vaccination
(Zuckerman et al, 1991). Finally, response to individual vaccines
was correlated with a number of clinical variables (age, white
blood cell count, polyclonal IgG level and current immunosup-
pressive therapy) using the Pearson Contingency Coefficient. A
contingency coefficient of ³ 0.4 indicated a probable correlation.
The significance of the correlation was investigated using the
Pearson  c2 test.
RESULTS
Specific antibodies to S. pneumoniae and response to
vaccination (Table 1)
Prior to vaccination, 3/48 patients (6%) had specific anti-pneumo-
coccal capsule polysaccharide antibodies at protective titres
(defined as titres greater than 1:640, the geometric mean titre of
the normal UK population). Thirty-one patients (70%) had titres
below the 10th centile titre of 1:80. Post-vaccination antibody
titres were available for 43 patients. Seventeen (40%) achieved
protective specific antibodies 4–6 weeks following vaccination. In
26 (61%), however, suboptimal titres were reached, and in 13
patients (30%) antibody titres remained below the 10th centile. A
good serological response to vaccination, defined as achieving a
fourfold increase in specific antibodies, was recorded in 24
patients (56%). The pre- and post-vaccination GMT for the popu-
lation were 1:53 and 1:286, indicating that this population as a
whole has poor antibody levels against S. pneumoniae even after
vaccination.
Specific antibodies to Hib and response to vaccination
(Table 2)
Prior to vaccination the antibody titres of the patient population
(n = 46) against this organism was comparable with results
obtained from the healthy UK adult population. The geometric
mean antibody titre was 1.06 mg l–1, with 25 patients (54%) having
suboptimal levels, and only one patient (2%) having < 0.15 mg l–1,
the minimum protective level. Following vaccination, paired sera
were available for 44 patients. Thirty-three patients (75%)
achieved protective antibody titres (> 1.0 mg ml–1) and the
geometric mean titre increased to 2.6 mg ml–1. Eighteen patients
(41%) achieved a good response to vaccination in terms of a four-
fold increase in antibody titre.
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Table 1 Response to Pneumovax II (total IgG). A protective titre is defined
as ³ 1/640, the geometric mean titre of the normal adult UK population
Pre-vaccination Post-vaccination 
(n = 48) (n = 43)
Protective antibody titre 3 6% 17 39%
Suboptimal antibody titre 45 94% 26 61%
Titre below 10th percentile 31 70% 13 30%
Fourfold increase in titre 24 56%
Geometric mean titre 1/53 1/287
Table 2 Response to ACT-HIB.
Pre-vaccination Post-vaccination 
(n = 46) (n = 44)
Protective antibody titre 21 46% 33 75%
Suboptimal antibody titre 25 54% 11 25%
Titre < 0.15 mg l–1 12 % 0
Geometric mean titre (mg l–1) 1.06 2.6
Four fold increase in titre 18 41%
A protective titre is defined as ³ 1.02 mg l–1, the geometric mean titre of the
normal UK adult population. The minimum protective level is 0.15 mg l–1Susceptibility to influenza and response to vaccination
(Table 3)
Prior to vaccination, no patients had protective titres to all three
influenza strains. Forty-one patients (85%) were susceptible to all
the strains, four patients (8.3%) had protection from one strain and
four patients (8.3%) had protection from two strains. In a healthy
adult population, approximately 50% of subjects would be
expected to have protective antibody titres against the two
influenza A strains (H1N1 and H3N2) with slightly lower antibody
titres to influenza B (unpublished data, PHLS).
Following vaccination, paired sera were available for 48
patients. Twenty-eight patients (58%) had a poor antibody
response (HI < 1/40) to all three antigens. Thirteen (27%)
patients achieved protective levels against H1N1, 15 patients
(31%) achieved protective levels against H3N2 and 15 patients
(31%) achieved protective levels against influenza B. Overall,
six patients (13%) developed protection against one strain and
five patients (10%) developed protection against two strains. Only
nine patients (19%), however, developed the required protective
titres against all three strains to be considered fully protected
against influenza. The pre- and post-vaccination GMTs for each
strain were low with none exceeding the levels required for a
protective response (Table 4).
Association of clinical variables with response to
vaccination (Table 5)
The responses to Pneumovax, combined influenza strains and
vaccination against Hib were correlated with a number of variables
using the Pearson Contingency Coefficient as a measure of agree-
ment. The variables tested were: age, white blood cell count,
serum polyclonal IgG level, administration of chemotherapy
within a week prior to vaccine, treatment with high-dose
chemotherapy and autologous peripheral blood stem cell trans-
plant within 6 months prior to vaccine and current treatment with
interferon a. Two variables were identified which had possible
associations with response to vaccination: undergoing stem cell
transplantation within 6 months pre-vaccination correlated with a
poor response to Hib vaccine (contingency coefficient 0.431, P =
0.04) and receiving chemotherapy within 7 days pre-vaccination
correlated with a poor response to influenza vaccination (contin-
gency coefficient 0.479, NS).
Clinical efficacy
No serious adverse reactions to vaccination were reported. Ten
patients reported upper respiratory tract symptoms and sent nose
and throat swabs for virus detection during the study period
(October 1997–January 1998). No cases of influenza were
confirmed.
DISCUSSION
The policy of the UK Department of Health is to offer annual
influenza vaccination as a routine to people with underlying
diseases that put them at special risk from this infection (HMSO,
1996). This is based on good epidemiological evidence that immu-
nization of those most at risk reduces hospital admissions and
deaths (Ahmed et al, 1995). Similarly, pneumococcal vaccination
is recommended for patients over 2 years of age in whom pneumo-
coccal infection is likely to be ‘more common and/or dangerous’
(HMSO, 1996). However, there is little information concerning the
efficacy of these vaccinations in patients with different types of
malignancies, whose degree of immune suppression and exposure
to cytotoxic drugs varies widely and may affect their ability to
mount an immune response. This is especially difficult in the case
of pneumococcal vaccination, where there is controversy as to
what constitutes the optimum protective antibody level, and anti-
body responses to only a few of the 23 capsule polysaccharides
are measured. In addition there is little information concerning
the duration of humoral response to vaccination especially in
immunocompromised individuals.
There are no recommendations for Hib immunization in adults
and data concerning the susceptibility of immunocompromised
populations to infection with this encapsulated organism is scarce.
Co-administration of the vaccines at different sites is safe and
immunogenic (Honkanen et al, 1996).
In a healthy adult population up to 50% of people have protec-
tive titres to circulating influenza A strains and slightly less to
influenza B strains (unpublished data, PHLS). Following vaccina-
tion, over 70% achieve protective titres against two or three strains
(Lorio et al, 1989). Of 48 myeloma patients, only two (4%) had
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Table 3 Response to influenza vaccination
Pre-vaccination Post-vaccination 
(n = 49) (n = 48)
Fully protected 0 9 19%
Protected against 0 strains 41 84% 28 59%
Protected against 1 strains 4 8% 6 13%
Protected against 2 strains 4 8% 5 10%
A protective antibody titre is defined as a reciprocal HI titre of ³ 40 for each
antigen. Full protection requires protective antibody titres to all three
influenza strains.
Table 4 Pre- and post-vaccination geometric mean titres against three
influenza antigens
H1N1 H3N2 B
Pre-vaccination 5.6 7.2 7.2
Post-vaccination 16.1 20.3 20.6
A titre of over 40 is protective.
Table 5 Association of response to vaccination with clinical variables
Patient variables Response to vaccination
Pneumovax II ACT-HIB Combined influenza
strains
Age < 50 0.158 0.042 0.251
WBC 0.119 0.137 0.274
Serum IgG 0.134 0.077 0.344
Chemotherapy within 7 days 0.161 0.082 0.479
PBSCT within 6 months 0.258 0.431 P = 0.04 0.311
Current interferon therapy 0.047 0.085 0.288
Contingency coefficient values quoted. Values ³ 0.4 suggest agreement.
P-values quoted for positive associations.protective titres to one influenza A strain and three (6%) had
protective titres to influenza B pre-vaccination. The population
studied is thus highly susceptible to influenza infection. In terms
of achieving protective levels of antibodies within 6 weeks, the
results of vaccination were disappointing with only 14 patients
(29%) achieving protection against two or more strains. Poor anti-
body responses to influenza vaccination have also been reported in
heart transplant patients (Admon et al, 1997). In lung cancer
patients, however, the response to influenza vaccine was 78%
(Anderson et al, 1999) and in children with acute lymphoblastic
leukaemia, titres of ³ 1/40 were found in over 68% of patients 6
months after immunization (Brydak et al, 1998). In this group,
serological responses were higher in samples taken at 6 months
post-vaccination compared with those from samples taken at 3
weeks post-vaccination; we intend to further investigate this
phenomenon in the myeloma patients. One small randomized
study investigated clinical efficacy of influenza vaccination in
myeloma patients, using the end point parameters of incidence of
upper respiratory tract infections and number of hospital admis-
sions during the study period (Musto and Carotenuto, 1997). The
authors concluded that influenza vaccine was effective in
myeloma patients although no serological analysis was carried
out. In our population, no confirmed cases of influenza were
recorded. However, there was only very mild influenza activity in
the UK during the winter of 1997–8 (Dedman et al, 1998), and
therefore the trial was not really a measure of efficacy. There are
no data on the efficacy of two-dose influenza vaccines in myeloma
patients but improved responses have not been shown in other
patient groups (Miotti et al, 1989; Iorio et al, 1997). Interestingly,
the addition of a third dose improved antibody responses in heart
transplant patients (Admon et al, 1997).
The degree of susceptibility of our population to infection with
S. pneumoniae is well demonstrated by the finding that 72% of
patients had prevaccination titres below the 10th percentile of the
normal adult cohort. The response to vaccination was again disap-
pointing; although 56% developed a fourfold increase in antibody
titre, the geometric mean titre remained low and 30% of patients
still had antibody titres below the 10th percentile. It is likely that
such poor responses to vaccination will also be poorly sustained.
Larger studies are required in myeloma patients and in other
immunosuppressed groups to address the issue of revaccination.
Pneumovax II is intended to be efficacious for 10 years and, under
current recommendations, the patients would not be revaccinated
within 6 years. Repeat vaccination seems to be safer than previ-
ously thought, however, and would seem desirable (Jackson et al,
1999).
Exposure and specific immunity to Hib was comparable to the
healthy adult population and there would seem to be no indication
for introducing this form of vaccination in these patients.
Some investigators have reported associations between
response to vaccination and patient age (Sullivan et al, 1990) and
serum IgG level (Gribabis et al, 1994). In this study, small patient
numbers precluded detection of significant associations between
response to vaccination and the variables considered but recent
chemotherapy and autologous peripheral blood stem cell trans-
plant showed positive correlation for poor responses. It is well
documented that antibody responses are poor within 2 years of
transplant (Parkkali et al, 1996) and generally recommended that
vaccinations be given at least 2 weeks prior to chemotherapy or
around 6 months after completion of treatment.
CONCLUSIONS
This study confirms that patients with multiple myeloma are
susceptible to infection with S. pneumoniae and influenza and
demonstrate impaired ability to mount a good humoral response to
vaccination. In particular, the extremely poor response to influenza
vaccination calls into question the policy of vaccinating patients
with myeloma using a conventional single-shot influenza vaccine.
This small study was unable to address many other clinical vari-
ables that will be of relevance such as vaccination responses in
MGUS (monoclonal gammopathy of uncertain significance) or
untreated myeloma, and in early versus late disease. Our findings
highlight the need for many more studies to further define humoral
and cellular vaccination responses in terms of clinical efficacy,
magnitude and duration of response in order to define suitable
immunization protocols for patients with multiple myeloma. New
adjuvants for vaccines and new vaccine delivery systems may
offer some hope of enhancing immunopriority in some groups of
immunosuppressed individuals.
ACKNOWLEDGEMENTS
We would like to thank Dr J North, Department of Immunology,
City Hospital, Birmingham for advice concerning interpretation of
serological results following Pneumovax and Hib vaccination, and
Mr J Linsell for his help with the data collation.
REFERENCES
Admon D, Engelhard D, Strauss N, Goldman N and Zakay-Rones Z (1997)
Antibody response to influenza immunization in patients after heart
transplantation. Vaccine 15: 1518–1522
Ahmed AH, Nicholson KG and Nguyen van Tam JS (1995) Reduction in mortality
associated with influenza vaccination during 1989–90 epidemic. Lancet 346:
591–595
Anderson H, Petrie K, Berrisford C, Charlett A, Thatcher N and Zambon M (1999)
Seroconversion after influenza vaccination in patients with lung cancer.
Br J Cancer 80: 219–220
Brydak LB, Rokicka-Milewska R, Machala M, Jackowska T and Sikorskå-Fic B
(1998) Immunogenicity of subunit trivalent influenza vaccine in children with
acute lymphoblastic leukaemia. Paediatr Infect Dis J 17: 126–129
Chakraverty, P (1971) Antigenic relationships between influenza B viruses. Bull
WHO 45: 755–766
Dedman DJ, Zambon M, Van Buynder P, Fleming DM, Watson JM and Joseph CA
(1998) Influenza surveillance in England and Wales: October 1997 to June
1998. Commun Dis Public Health 1: 244–251
Deresinski SC and Stevens DA (1974) Disseminated herpes simplex in untreated
multiple myeloma. Paradox of present concepts of immune defects. Oncology
30: 318–323
Fahey J, Scoggin R, Utz J and Szwed C (1963). Infection, antibody response and
gamma globulin components in myeloma and macroglobulinaemia. Am J Med
35: 698–707
Gribabis DA, Panayiotidis P, Boussiotis VA, Hannoun C and Pangalis GA (1994)
Influenza virus vaccine in B-cell chronic lymphocytic leukaemia patients.
Acta Haematol 91: 115–118
Hazelwood M, Nusrat R, Kumararatne DS, Goodall M, Raykundalia C, Gong Wang
D, Joyce HJ, Milford-Wards A, Forte M and Pahor A (1993) The acquisition of
anti-pneumococcal capsular polysaccharide, Haemophilus influenzae type b
and tetanus toxoid antibodies, with age, in the UK. Clin Exp Immunol 93: 1–8
HMSO (1996) Immunisation against Infectious Disease. Department of Health: London
Hobson D, Curry RL, Beare AS and Ward-Gardner A (1972) The role of serum
haemagglutination-inhibiting antibody in protection against challenge infection
with influenza A2 and B viruses. J Hygiene Lond 70: 767–777
Honkanen PO, Keistinen T and Kivela SL (1996) Reactions following
administration of influenza vaccine alone or with pneumococcal vaccine to the
elderly. Arch Intern Med 156: 205–206
1264 JD Robertson et al
British Journal of Cancer (2000) 82(7), 1261–1265 © 2000 Cancer Research CampaignIorio AM, Alatri A, Francisci D, Preziosi R, Neri M, Donatelli I, Castrucci MR,
Biasio LR, Tascini C, Iapoce R, Pierucci P and Baldelli F (1997)
Immunogenicity of influenza vaccine (1993–94 winter season) in HIV-
seropositive and -seronegative ex-intravenous drug users. Vaccine 15:
97–102
Jackson LA, Benson P, Sneller VP, Butler JC, Thompson RS, Chen RT, Lewis L S,
Carlone G, De Stefano F, Holder P, Lezhava T and Williams WW (1999)
Safety of revaccination with pneumococcal polysaccharide vaccine. J Am Med
Assoc 281: 243–248
Lorio AM, Rivosecchi P, Zei M, Neri M, Merlett L (1989) Immune response to
trivalent inactivated influenza vaccine in young and elderly subjects. Vaccine 7:
303–306
Luque R, Brieva JA, Moreno A, Manzanal A, Escribano L, Villarrubia J, Velasco JL,
Lopez-Jimenez J, Cervero C, Otero MJ, Martinez J, Bellas C and Roldan
(1998) Normal and clonal B lineage cells can be distinguished by their
differential expression of B cell antigens and adhesion molecules in peripheral
blood from multiple myeloma (MM) patients–diagnostic and clinical
implications. Clin Exp Immunol 112: 410–418
Lyall EGH, Charlett A, Watkins P and Zambon M (1997) Response to 
influenza virus vaccine in vertical HIV infection. Arch Dis Childhood 76:
215–218
Miotti PG, Nelson KE, Dalabetta GA, Farzadegan H, Margolock J and Clements
M L (1989). The influence of HIV on antibody responses to a two-dose
regimen of influenza vaccine. J Am Med Assoc 262: 779–783
Musto P and Carotenuto M (1997) Vaccination against influenza in multiple
myeloma (letter). Br J Haematol 97: 505–506
Norden CW (1980) Infections in patients with multiple myeloma [editorial]. Arch
Intern Med 140: 1150–1151
Parkkali T, Kayhty H, Ruutu T, Volin L, Eskola J and Ruutu P (1996) A comparison
of early and late vaccination with Haemophilus influenzae type b conjugate and
pneumococcal polysaccharide vaccines after allogeneic BMT. Bone Marrow
Transplant 18: 961–996
Ringden O (1997) Allogeneic bone marrow transplantation for hematological
malignancies controversies and recent advances. Acta Oncol 36: 549–564
Savage DG, Lindenbaum J and Garrett TJ (1982) Biphasic pattern of bacterial
infection in multiple myeloma. Ann Intern Med 96: 47–50
Sullivan KM, Monto AS and Foster DA (1990) Antibody response to inactivated
influenza vaccines of various antigenic concentrations. J Infect Dis 161: 333–333
Zuckerman MA, Wood J, Chakraverty P, Taylor J, Heath AB, Oxford JS (1991)
Serological responses in volunteers to inactivated trivalent subunit influenza
vaccine: antibody reactivity with epidemic influenza A and B strains and
evidence of a rapid immune response. J Med Virol 33: 133–137
Vaccination responses in multiple myeloma 1265
British Journal of Cancer (2000) 82(7), 1261–1265 © 2000 Cancer Research Campaign